<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04830215</url>
  </required_header>
  <id_info>
    <org_study_id>331-201-00289</org_study_id>
    <nct_id>NCT04830215</nct_id>
  </id_info>
  <brief_title>Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder</brief_title>
  <official_title>A Phase 4, Multicenter, Open-label, Interventional Trial to Assess the Effects on Engagement of Flexible-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy for the Treatment of Adults With Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Lundbeck Canada Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Otsuka Canada Pharmaceutical Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The clinical trial will investigate the effect of brexpiprazole on the concept of life&#xD;
      engagement in patients with MDD with a current depressive episode.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 4, multicenter, open-label, flexible dose trial designed to assess the&#xD;
      effects of brexpiprazole (flexible dose; 0.5 to 2 mg QD) as adjunctive therapy to ADT on life&#xD;
      engagement in patients with MDD. This trial is being conducted in line with the Canadian&#xD;
      Product Monograph.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">April 2021</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Inventory of Depressive Symptomatology Self-Report (IDS-SR) 10-life engagement</measure>
    <time_frame>Change from baseline to Week 8</time_frame>
    <description>Change from baseline to Week 8 in IDS-SR-10- life engagement</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inventory of Depressive Symptomatology Self-Report (IDS-SR) Total score</measure>
    <time_frame>Change from baseline to Week 8</time_frame>
    <description>Change from baseline to Week 8 in IDS-SR Total score</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Brexpiprazole</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Brexpiprazole as a flexible dose; 0.5 to 2 mg/day and patient will continue on the stable dose of ADT that they were taking at screening.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brexpiprazole</intervention_name>
    <description>Brexpiprazole (flexible dose; 0.5 to 2 mg once daily [QD]) as adjunctive therapy to antidepressant therapy (ADT)</description>
    <arm_group_label>Brexpiprazole</arm_group_label>
    <other_name>OPC-34712</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female patients (outpatients) between the regional age of majority (18 or 19&#xD;
             years of age) to 65 years of age, inclusive, at the time of informed consent.&#xD;
&#xD;
          -  Primary diagnosis of MDD and in a current non-psychotic MDE as defined by DSM-5&#xD;
             criteria, who have been outpatients for at least 4 weeks, and have an inadequate&#xD;
             response, per investigator judgment, to 1 or 2 adequate treatments of ADTs in their&#xD;
             current MDE, including current ADT.&#xD;
&#xD;
          -  Patients with a Patient Health Questionnaire 9-item scale (PHQ-9) â‰¥ 15 at the&#xD;
             screening and baseline visits, if separate.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients currently or previously treated with brexpiprazole including patients who&#xD;
             received brexpiprazole in any prior clinical trial.&#xD;
&#xD;
          -  Patients with a concurrent DSM-5 diagnosis of the following will be excluded:&#xD;
&#xD;
               -  Schizophrenia or schizoaffective disorder&#xD;
&#xD;
               -  Bipolar I or bipolar II disorder&#xD;
&#xD;
               -  Post-traumatic stress disorder&#xD;
&#xD;
               -  Dementia&#xD;
&#xD;
               -  Eating disorder&#xD;
&#xD;
               -  Borderline personality disorder&#xD;
&#xD;
               -  Antisocial personality disorder&#xD;
&#xD;
          -  Patients with a suicidality score of 3 based on IDS-SR suicidality item 18 or patients&#xD;
             who, in the opinion of the investigator, presents a serious risk of suicide.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eva Kohegyi, MD</last_name>
    <role>Study Director</role>
    <affiliation>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Otsuka Call Center</last_name>
    <phone>844-687-8522</phone>
    <email>OtsukaUS@druginfo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chatham-Kent Clinical Trials Research Centre</name>
      <address>
        <city>Chatham</city>
        <state>Ontario</state>
        <zip>N7L 1C1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>March 29, 2021</study_first_submitted>
  <study_first_submitted_qc>April 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2021</study_first_posted>
  <last_update_submitted>April 2, 2021</last_update_submitted>
  <last_update_submitted_qc>April 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MDD</keyword>
  <keyword>Depression</keyword>
  <keyword>Brexpiprazole</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brexpiprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

